A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL
A Clinical Study to Investigate Safety, Tolerability, and Preliminary Efficacy of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Adult Patients With Relapsed or Refractory B-NHL is a PHASE1 clinical asset sponsored by Ruijin Hospital in B-cell Non-Hodgkin Lymphoma. SEO and diligence focus: ABO2203 Injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: B-cell Non-Hodgkin Lymphoma
Modality: small molecule
Target: ABO2203 Injection
Sponsor: Ruijin Hospital
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: ABO2203 Injection
View original source fields
Condition raw: B-cell Non-Hodgkin Lymphoma
Condition normalized: B-cell Non-Hodgkin Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: ABO2203 Injection
Target normalized: ABO2203 Injection